Cargando…

ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile

The Middle East is underrepresented in psychosis research. The ARAS recent onset acute phase psychosis survey (ARAS) is a longitudinal cohort across multiple centers in Iran, established to investigate characteristics, determinants and early course of psychosis in a non-Western, Middle East context....

Descripción completa

Detalles Bibliográficos
Autores principales: Farhang, Sara, Shirzadi, Maryam, Alikhani, Rosa, Alizadeh, Behrooz Z., Bruggeman, Richard, Veling, Wim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675807/
https://www.ncbi.nlm.nih.gov/pubmed/36402780
http://dx.doi.org/10.1038/s41537-022-00295-z
_version_ 1784833451936972800
author Farhang, Sara
Shirzadi, Maryam
Alikhani, Rosa
Alizadeh, Behrooz Z.
Bruggeman, Richard
Veling, Wim
author_facet Farhang, Sara
Shirzadi, Maryam
Alikhani, Rosa
Alizadeh, Behrooz Z.
Bruggeman, Richard
Veling, Wim
author_sort Farhang, Sara
collection PubMed
description The Middle East is underrepresented in psychosis research. The ARAS recent onset acute phase psychosis survey (ARAS) is a longitudinal cohort across multiple centers in Iran, established to investigate characteristics, determinants and early course of psychosis in a non-Western, Middle East context. Here, baseline characteristics of the ARAS cohort are reported. The ARAS cohort enrolled patients with recent onset psychosis from September 2018 to September 2021 in East Azerbaijan, Kermanshah and Tehran, including Iranian patients from different sociocultural contexts. The baseline assessment included demographics, socioeconomic status, clinical (positive, negative, depressive symptoms) and psychosocial (religiosity, social support, self-stigma) characteristics, cognitive functioning, metabolic profile, substance use and medication use measured by validated questionnaires. These assessments will be followed up after one and five years. A total of 500 patients with a first episode of psychosis were enrolled from three provinces in Iran. With 74.1% being male, the mean age (SD) of patients was 32.3 (9.7) years. Nearly a quarter of patients was diagnosed with schizophrenia and 36.8% with substance induced psychotic disorder. Amphetamine (24%) and opium (12%) use were common, cannabis use was not (5%). Only 6.1% of patients lived alone while 29% of patients was married and had children. The majority of them had achieved secondary educational level and 34% had a paid job. The most common antipsychotic treatment was risperidone. There was a wide range for scores of PANSS, with 9.4% having dominant negative symptoms. The most common prescribed medication was risperidone. Near to 40% of patients had noticeable signs of depression and prevalence of metabolic syndrome was 13.4%. The majority of patients (57.2%) had moderate and 5.4% reported to have severe disability. More than 30% reported to be highly religious. Patients had the highest satisfaction with people living with, and the lowest for finance and job.
format Online
Article
Text
id pubmed-9675807
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96758072022-11-21 ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile Farhang, Sara Shirzadi, Maryam Alikhani, Rosa Alizadeh, Behrooz Z. Bruggeman, Richard Veling, Wim Schizophrenia (Heidelb) Article The Middle East is underrepresented in psychosis research. The ARAS recent onset acute phase psychosis survey (ARAS) is a longitudinal cohort across multiple centers in Iran, established to investigate characteristics, determinants and early course of psychosis in a non-Western, Middle East context. Here, baseline characteristics of the ARAS cohort are reported. The ARAS cohort enrolled patients with recent onset psychosis from September 2018 to September 2021 in East Azerbaijan, Kermanshah and Tehran, including Iranian patients from different sociocultural contexts. The baseline assessment included demographics, socioeconomic status, clinical (positive, negative, depressive symptoms) and psychosocial (religiosity, social support, self-stigma) characteristics, cognitive functioning, metabolic profile, substance use and medication use measured by validated questionnaires. These assessments will be followed up after one and five years. A total of 500 patients with a first episode of psychosis were enrolled from three provinces in Iran. With 74.1% being male, the mean age (SD) of patients was 32.3 (9.7) years. Nearly a quarter of patients was diagnosed with schizophrenia and 36.8% with substance induced psychotic disorder. Amphetamine (24%) and opium (12%) use were common, cannabis use was not (5%). Only 6.1% of patients lived alone while 29% of patients was married and had children. The majority of them had achieved secondary educational level and 34% had a paid job. The most common antipsychotic treatment was risperidone. There was a wide range for scores of PANSS, with 9.4% having dominant negative symptoms. The most common prescribed medication was risperidone. Near to 40% of patients had noticeable signs of depression and prevalence of metabolic syndrome was 13.4%. The majority of patients (57.2%) had moderate and 5.4% reported to have severe disability. More than 30% reported to be highly religious. Patients had the highest satisfaction with people living with, and the lowest for finance and job. Nature Publishing Group UK 2022-11-19 /pmc/articles/PMC9675807/ /pubmed/36402780 http://dx.doi.org/10.1038/s41537-022-00295-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Farhang, Sara
Shirzadi, Maryam
Alikhani, Rosa
Alizadeh, Behrooz Z.
Bruggeman, Richard
Veling, Wim
ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile
title ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile
title_full ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile
title_fullStr ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile
title_full_unstemmed ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile
title_short ARAS recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in Iran—the cohort profile
title_sort aras recent onset acute phase psychosis survey, a prospective observational cohort of first episode psychosis in iran—the cohort profile
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675807/
https://www.ncbi.nlm.nih.gov/pubmed/36402780
http://dx.doi.org/10.1038/s41537-022-00295-z
work_keys_str_mv AT farhangsara arasrecentonsetacutephasepsychosissurveyaprospectiveobservationalcohortoffirstepisodepsychosisiniranthecohortprofile
AT shirzadimaryam arasrecentonsetacutephasepsychosissurveyaprospectiveobservationalcohortoffirstepisodepsychosisiniranthecohortprofile
AT alikhanirosa arasrecentonsetacutephasepsychosissurveyaprospectiveobservationalcohortoffirstepisodepsychosisiniranthecohortprofile
AT arasrecentonsetacutephasepsychosissurveyaprospectiveobservationalcohortoffirstepisodepsychosisiniranthecohortprofile
AT alizadehbehroozz arasrecentonsetacutephasepsychosissurveyaprospectiveobservationalcohortoffirstepisodepsychosisiniranthecohortprofile
AT bruggemanrichard arasrecentonsetacutephasepsychosissurveyaprospectiveobservationalcohortoffirstepisodepsychosisiniranthecohortprofile
AT velingwim arasrecentonsetacutephasepsychosissurveyaprospectiveobservationalcohortoffirstepisodepsychosisiniranthecohortprofile